Get the Stockscreener App
1.61
5.29%
-0.09
After Hours:
1.61
Allarity Therapeutics Inc stock is traded at $1.61, with a volume of 156.95K.
It is down -5.29% in the last 24 hours and up +15.00% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
See More
Previous Close:
$1.70
Open:
$1.71
24h Volume:
156.95K
Relative Volume:
0.79
Market Cap:
$25.62M
Revenue:
$345.00K
Net Income/Loss:
$-11.25M
P/E Ratio:
-2.2308
EPS:
-0.7217
Net Cash Flow:
$-16.70M
1W Performance:
-1.83%
1M Performance:
+15.00%
6M Performance:
+41.23%
1Y Performance:
+101.40%
1-Day Range:
$1.56
$1.715
1-Week Range:
$1.55
$1.75
52-Week Range:
$0.7687
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.61 | 27.05M | 345.00K | -11.25M | -16.70M | -0.7217 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Stock (ALLR) Latest News
Are medical stocks lagging Allarity Therapeutics, Inc. (ALLR) this year? - MSN
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance
Amended and Restated Management Services Agreement Between Allarity Therapeutics, Inc. and Ljungaskog Consulting AB Effective June 1, 2026 - Minichart
Allarity Therapeutics Updates CEO Management and Compensation Agreement - TipRanks
Allarity (NASDAQ: ALLR) updates CEO pay and severance terms - Stock Titan
Number of shareholders of Allarity Therapeutics, Inc. – NASDAQ:ALLR - TradingView
ALLR Q1 2026 Earnings: Narrower Loss Surprises as Pre-Revenue Biotech Advances PipelineGuidance Downgrade Alert - The Legal Advocate
Allarity Therapeutics (ALLR) Faces Selling Pressure, Holds Above Key SupportVolatility Smile - thelegaladvocate.com
Allarity Therapeutics (ALLR) Surges 6.6% as Volume Picks Up, Testing Key ResistanceOption Breadth - The Legal Advocate
Allarity (ALLR) Posts Q1 2026 Earnings Beat — Here's What Drove ItPre-Announcement Alert - The Legal Advocate
Allarity (ALLR) Delivers Q1 2026 Beat — EPS $-0.17 vs $-0.22 ExpectedEarnings Yield Spread - The Legal Advocate
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Allarity Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Allarity Therapeutics Advances Stenoparib Development for Cancer Treatments and Strengthens Financial Position - Quiver Quantitative
Allarity Therapeutics Q1 net loss per share narrows - TradingView
U.S. VA backs trial of Allarity cancer drug for relapsed lung patients - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Allarity Therapeutics (ALLR) posts Q1 2026 loss but lifts cash with $20M notes - Stock Titan
Allarity Therapeutics (ALLR) CEO receives 200,000-share RSU equity grant - Stock Titan
Why Allarity (ALLR) Just Dropped -1.30% — What to Watch 2026-05-14Trade Entry - newser.com
Director Jesper Hoeiland receives 25,000-share grant at Allarity (ALLR) - Stock Titan
Director Jesper Hoeiland joins Allarity Therapeutics (ALLR) with initial Form 3 filing - Stock Titan
Allarity Therapeutics Advances Stenoparib, a Dual PARP and WNT Inhibitor with DRP® Companion Diagnostic, in Phase 2 Cancer Trials - Minichart
Allarity Highlights Stenoparib Progress in New Investor Presentation - TipRanks
Allarity details stenoparib data, CEO to speak in Europe | ALLR 8-K Filing - Stock Titan
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - The Manila Times
Allarity Therapeutics CEO Thomas Jensen to Speak at Precision Medicine Forum Europe 2026 - Quiver Quantitative
Allarity CEO to outline cancer drug trial work at Stockholm forum - Stock Titan
Director at Allarity Therapeutics (ALLR) receives 45,000 RSUs in grant - Stock Titan
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
Allarity Therapeutics Advances Stenoparib Toward Phase 3 and FDA Approval in Ovarian Cancer with Manufacturing Milestone - Minichart
Stenoparib Phase 3 manufacturing on track as Allarity (NASDAQ: ALLR) preps trials - Stock Titan
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - Investing News Network
Allarity advances stenoparib manufacturing for pivotal trial By Investing.com - Investing.com South Africa
Allarity advances stenoparib manufacturing for pivotal trial - Investing.com India
Allarity readies ovarian cancer drug with no more manufacturing cash due - Stock Titan
What Allarity (ALLR) is doing to earn customer loyalty (Institutional Demand) 2026-05-05PCR Extreme - The Legal Advocate
[ARS] Allarity Therapeutics, Inc. SEC Filing - Stock Titan
Allarity Therapeutics (NASDAQ: ALLR) details 2026 votes on ELOC, pay and equity plan - Stock Titan
Equity grant gives Allarity Therapeutics (ALLR) officer 133,333 RSUs - Stock Titan
Allarity Therapeutics (ALLR) CFO awarded 150,000 restricted stock units - Stock Titan
USPTO allows Allarity (NASDAQ: ALLR) stenoparib DRP patent with exclusivity to 2039 - Stock Titan
Allarity receives USPTO patent notice for stenoparib diagnostic - Investing.com UK
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office - Investing News Network
Allarity receives USPTO patent notice for stenoparib diagnostic By Investing.com - Investing.com Australia
Allarity Therapeutics announces that the stenoparib drp® test has received a notice of allowance from the US Patent and Trademark Office - marketscreener.com
SEC Form 424B3 filed by Allarity Therapeutics Inc. - Quantisnow
255,103 Shares Registered for Resale by 3i, LP — Allarity (NASDAQ: ALLR) - Stock Titan
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):